Cyclerion Therapeutics
CYCN
17 hedge funds and large institutions have $595K invested in Cyclerion Therapeutics in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
3.55% less ownership
Funds ownership: 11.3% → 7.76% (-3.5%)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
44% less capital invested
Capital invested by funds: $1.06M → $595K (-$460K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$118K |
| 2 |
Two Sigma Investments
New York
|
+$36.1K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$12K |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$16 |
| 5 |
Barclays
London,
United Kingdom
|
+$14 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$26.3K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.18K |
| 3 |
PW
Pandora Wealth
Oakbrook Terrace,
Illinois
|
-$32 |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$32 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$5 |
CYCN Hedge Fund Activity: Q3 2025 in Review
17 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Cyclerion Therapeutics (CYCN) for Q3 2025, worth a combined $595K — down 44% from $1.06M a quarter earlier.
Fund positioning in CYCN was balanced in Q3 2025: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 3 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $118K. The largest seller was UBS Group, cutting an estimated $26.3K.
- 17 institutional investors held Cyclerion Therapeutics (CYCN) as of Q3 2025, unchanged from Q2 2025.
- Funds reported $595K of Cyclerion Therapeutics stock for Q3 2025, down 44% quarter-over-quarter.
- 3 funds opened new Cyclerion Therapeutics positions in Q3 2025 and 3 closed out, a net change of 0 holders.
- The largest Cyclerion Therapeutics buyer in Q3 2025 was DRW Securities, an estimated $118K added.
- The largest Cyclerion Therapeutics seller in Q3 2025 was UBS Group, an estimated $26.3K sold.
Based on aggregated 13F filings for Q3 2025.